Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.
Repeated administration of opioids produces long-lasting changes in micro-opioid receptor (MOR) signaling that underlie behavioral changes such as tolerance. Mitogen-activated protein kinase (MAPK) pathways, including MAPK extracellular signal-regulated kinases (ERK1/2), are modulated by opioids and are known to produce long-lasting changes in cell signaling. Thus, we tested the hypothesis that ERK1/2 activation contributes to the development and/or expression of morphine tolerance mediated by the periaqueductal gray (PAG). Changes in phosphorylated ERK1/2 expression were assessed with confocal microscopy and compared to behavioral measures of tolerance to the antinociceptive effects of chronic morphine administration. Repeated microinjection of morphine into the PAG produced tolerance and caused a significant increase in ERK1/2 phosphorylation, an effect not evident with acute morphine microinjection. Microinjection of the MAPK/ERK kinase inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene ethanolate (U0126), into the PAG had no effect on antinociception produced by acute morphine administration. However, repeated coadministration of U0126 and morphine into the PAG blocked ERK1/2 phosphorylation and enhanced the development of morphine tolerance. Coadministration of U0126 with morphine only on the test day also enhanced the expression of morphine tolerance. Administration of the irreversible opioid receptor antagonist beta-chlornaltrexamine blocked the activation of ERK1/2 caused by repeated morphine microinjections, demonstrating that ERK1/2 activation was a MOR-mediated event. In summary, these studies show that chronic morphine administration alters ERK1/2 signaling and that disruption of ERK1/2 signaling enhances both the development and expression of morphine tolerance. Contrary to expectations, these data indicate that ERK1/2 activation opposes the development of morphine tolerance.
Macey
Tara A
TA
Department of Psychology, Washington State University Vancouver, Vancouver, Washington 98686, USA.
Bobeck
Erin N
EN
Hegarty
Deborah M
DM
Aicher
Sue A
SA
Ingram
Susan L
SL
Morgan
Michael M
MM
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D004361:Drug Tolerance; D004789:Enzyme Activation / Q000187:drug effects*; D007150:Immunohistochemistry; D008297:Male; D008845:Microinjections; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009020:Morphine / Q000494:pharmacology*; D010147:Pain Measurement / Q000187:drug effects; D010487:Periaqueductal Gray / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000701:Analgesics, Opioid; D009020:Morphine; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
Curr Opin Neurobiol. 2004 Jun;14(3):311-7
15194111
Pain. 1989 Oct;39(1):103-107
2812847
J Physiol. 1999 Apr 1;516 ( Pt 1):219-25
10066936
Neuropharmacology. 2007 Jun;52(8):1580-5
17445843
Physiol Rev. 2001 Jan;81(1):299-343
11152760
Brain Res. 1976 Feb 27;103(3):501-13
1252940
Brain Res. 2005 Jun 14;1047(1):65-71
15878767
J Neurochem. 2000 Jan;74(1):414-22
10617147
Behav Neurosci. 1999 Aug;113(4):833-9
10495091
Eur J Neurosci. 2001 Oct;14(7):1091-104
11683901
J Neurochem. 1998 Feb;70(2):635-45
9453557
Pharmacol Biochem Behav. 2007 Nov;88(1):39-46
17764731
Pharmacol Biochem Behav. 2006 Sep;85(1):214-9
16979226
Eur J Biochem. 2003 Aug;270(16):3291-9
12899687
Curr Opin Pharmacol. 2005 Feb;5(1):60-8
15661627
Neuropsychopharmacology. 2008 Sep;33(10):2494-504
18046309
FEBS Lett. 2001 Jul 27;502(1-2):21-4
11478941
Brain Res. 2005 Oct 19;1059(2):173-8
16182261
J Pharmacol Exp Ther. 2004 Aug;310(2):774-82
15056728
FASEB J. 2007 Aug;21(10):2455-65
17384143
Nat Rev Neurosci. 2004 Mar;5(3):173-83
14976517
Neuron. 2002 May 30;34(5):807-20
12062026
Neurosci Lett. 2002 May 17;324(2):97-100
11988336
J Neurosci. 1998 Dec 15;18(24):10269-76
9852564
J Neurosci. 2005 Mar 23;25(12):3192-8
15788776
Cell Signal. 1997 May-Jun;9(3-4):237-48
9218123
J Comp Neurol. 2001 Feb 5;430(2):200-8
11135256
Brain Res. 1987 Oct 27;424(2):311-9
3676830
Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56
16678156
J Biol Chem. 2006 Nov 10;281(45):34515-24
16982618
J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
11504778
J Biol Chem. 2005 Jul 29;280(30):27662-9
15944153
Biochem Pharmacol. 1997 Oct 1;54(7):809-18
9353135
Eur J Neurosci. 1998 Mar;10(3):1196-201
9753188
J Neurosci. 1996 Aug 1;16(15):4707-15
8764658
J Neurosci. 1995 Feb;15(2):1285-97
7532701
J Neurochem. 2004 Jul;90(1):220-30
15198681